Convatec Group (FRA:2CV) Other Current Liabilities: €235 Mil (As of Dec. 2025)


FRA:2CV Convatec Group PLC FRA:2CV
77 GF Score
Price €2.54
GF Value €2.98
! 4 Warning Signs
View Full Analysis

What is Convatec Group Other Current Liabilities?

Convatec Group FRA:2CV +3.25% 77 Other Current Liabilities is €235 Mil as of Dec. 2025. GuruFocus rates FRA:2CV with a GF Score™ of 77/100 and a GF Value™ of €2.98. The stock has 4 warning signs investors should review.

Convatec Group's other current liabilities for the quarter that ended in Dec. 2025 was €235 Mil.

Convatec Group's quarterly other current liabilities declined from Dec. 2024 (€287 Mil) to Jun. 2025 (€55 Mil) but then increased from Jun. 2025 (€55 Mil) to Dec. 2025 (€235 Mil).

Convatec Group's annual other current liabilities declined from Dec. 2023 (€293 Mil) to Dec. 2024 (€287 Mil) and declined from Dec. 2024 (€287 Mil) to Dec. 2025 (€235 Mil).

Convatec Group Other Current Liabilities Related Terms

Convatec Group Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Convatec Group's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Convatec Group Other Current Liabilities Chart

Convatec Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 188.95 322.00 293.44 286.50 234.85

Convatec Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.44 14.68 286.50 55.40 234.85
FRA:2CV
77GF Score
Convatec Group PLC FRA:2CV
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Convatec Group Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €235 Mil mean?
Convatec Group (FRA:2CV) has a Other Current Liabilities of €235 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Convatec Group.
Is Convatec Group's Other Current Liabilities too high?
Convatec Group's current Other Current Liabilities is €235 Mil. Overall, Convatec Group has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's Other Current Liabilities compare to ISRG and BDX?
Convatec Group's Other Current Liabilities of €235 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Convatec Group. Convatec Group's current Other Current Liabilities is €235 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Convatec Group (FRA:2CV) has a current Other Current Liabilities of €235 Mil. The stock's GF Value™ is €2.98, compared to a current price of €2.54 — trading 14.8% below its estimated fair value. The current Other Current Liabilities is €235 Mil. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Convatec Group (FRA:2CV), the current Other Current Liabilities is €235 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Convatec Group (FRA:2CV) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of €2.54 is trading 14.8% below its estimated GF Value™ of €2.98.

Key valuation signals for FRA:2CV:

  • Other Current Liabilities: €235 Mil
  • GF Value™: €2.98 vs. price of €2.54 (14.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the FRA:2CV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score

Get the complete analysis for FRA:2CV

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price
€2.98
GF Value